US EditionA Paradigm Shift: Final 5-Year Overall Survival Results from CheckMate 816 in Resectable NSCLC - ILCN.org (ILCN/WCLC)
Summary by ILCN.org (ILCN/WCLC)
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
A Paradigm Shift: Final 5-Year Overall Survival Results from CheckMate 816 in Resectable NSCLC - ILCN.org (ILCN/WCLC)
The CheckMate 816 trial, which evaluated neoadjuvant nivolumab in combination with chemotherapy, demonstrated a significant survival advantage versus chemotherapy alone in patients with resectable non-small cell lung cancer (NSCLC). Patrick Forde, MD Additionally, data confirmed a durable event-free survival (EFS) benefit. Patrick M. Forde, MD, PhD, Trinity St. James’s Cancer Institute, Trinity College Dublin, presented the latest and final ove…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
